Tagged with R

Switzerland Stefan Frefel, CEO of Bilfinger Industrial Services in Switzerland, outlines Bilfinger’s core offering of maintenance and engineering services to the pharmaceutical industry, the importance of the Swiss affiliate to the global group, and how the company is positioning itself at the forefront of digital disruption and other new industry trends.…

Austria Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution…

Canada Linda Tibbits, general manager at Pierre Fabre Dermo-Cosmetics in Canada takes us back to the beginnings of the French company in the country, where its initial success was driven by the harmonic relationship between Pierre Fabre himself and Jean Coutu, founder of Canada’s largest pharmacy network. She further talks portfolio…

India With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen – have stepped up with innovative initiatives to fill the gaps. “Economists such as Michael Porter see Arogya Parivar as a…

Serbia Ronald Seeliger, CEO of Hemofarm group, arrived in Serbia during turbulent times in CEE. Following a strict program of reinvestment, local expertise, and innovative strategies, Hemofarm surged forwards, developing into the pharmaceutical powerhouse that we see today. In this interview in the newly renovated offices in Belgrade, Seeliger sheds light…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

India Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how OPPI is helping to shape the Indian healthcare system. Please introduce yourself to our international readers and your journey to…

Switzerland Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies, and becoming a “flexible service provider.” Two years on from LabCorp’s headline-making acquisition of Covance, how has the integration process…

Brazil Gaetano Crupi, president and general manager of BMS in Brazil, leverages his long-standing experience at the head of prestigious pharmaceutical companies’ affiliates to provide an insightful overview of the key success factors to consider in the Brazilian market. He also documents BMS’ commitment to being a frontrunner in the medical,…

Canada Colette Rivet, executive director of the Cannabis Canada Association, leading Canadian licensed medical cannabis producers, talks regulatory challenges, upcoming opportunities, export ambitions and collaboration with the provincial and federal government in light of the upcoming legalization of cannabis for adult use in Canada. Colette, can you introduce the Cannabis Canada…

Poland Samantha Kingdom, general manager of Amgen Poland, highlights her strategy to be a significant contributor within the Polish healthcare space, while delivering highly innovative products to significantly improve Polish patients’ lives. Furthermore, she highlights the strong commitment of Amgen Poland to remain at the forefront of the clinical trials landscape,…

Japan Number of consultations for drugs in Japan by category in 2016. Oncology drugs leads the way, followed by gastrointestinal drugs and respiratory tract drugs. The launch of new medicines for major non-communicable diseases in Japan from 2004-2016 in terms of both applications and approvals. Regenerative medicine product approvals in Japan…